Moderna COVID-19 Vaccine Confirmed to Be Highly Effective by FDA Ahead of Expected Approval

The FDA analysis confirms Moderna’s earlier assessment of an efficacy rate of 94.1% for its COVID-19 vaccine in a trial of 30,000 people. However, the FDA found the vaccine to be less effective in older people, as it had a higher effectiveness of 96% in people aged between 18 to 65 years, as compared to 86% for people aged 65years and older.

The FDA's analysis further supported authorization of Moderna's COVID-19 vaccine for emergency use as the agency noted that the vaccine has a "favorable safety profile" and "no specific safety concerns identified that would preclude issuance of an EUA."

Related Links:
Moderna, Inc.